HIV fusion inhibitors, such as the membrane fusion inhibitor T20 (Fuzeon, enfuvirtide) and the C-C chemokine receptor type 5 (CCR5) blocker maraviroc (Selzentry), are currently utilized in combination therapy for HIV-1 infection. Here, CCR5 is linked to HIV-1 infection.